This website uses cookies. By using the site you are agreeing to our Privacy Policy.


HOME >> Investor Relations >> Message Archive (January 1, 2020)

PRINT

To Our Investors

Happy New Year from Japan Tissue Engineering Co., Ltd.
We would like to take this opportunity to express our deep appreciation for our shareholders and those who have always supported and guided Japan Tissue Engineering Co., Ltd. (J-TEC). We also ask you for continuous support this year.

Masataka Akiyama  Ken-ichiro Hata

Reflections on 2019

Half a year has already passed since our management structure changed. At our shareholders’ meeting in June, 2019, we informed you of our goals for the new structure. As we look back on 2019, let us explain the progress toward each goal.
Our first goal was the advancement of our development pipelines and the establishment of an innovative production system for regenerative medical products. For the acceleration of our development pipelines, we were able to advance, under the Act on Securing Safety of Regenerative Medicine, medical treatment not covered by health insurance for the use of autologous cultured epidermis with melanocytes for the treatment of vitiligo vulgaris, as well as successfully advancing corporate clinical trials to gain approval for manufacturing and selling this epidermis in accordance with the Law on Securing Quality, Efficacy and Safety of Products Including Pharmaceuticals and Medical devices. We similarly conducted corporate clinical trials for the treatment of post-traumatic secondary knee osteoarthritis using autologous cultured cartilage. For the establishment of an innovative production system for regenerative medical products, we have been combining our manufacturing experience and know-how of the past 20 years with the manufacturing technologies of FUJIFILM to work on multiple internal projects.
Our second goal was the enhancement of sales capabilities using group synergy. For the autologous cultured cartilage JACC, we have been pursuing the simplification of transplantation techniques by introducing artificial collagen membrane to attract new medical institution clients. We were also able to introduce the 3D image analysis system "SYNAPSE VINCENT" to those medical institutions already using JACC, to start proposal activities.
In March last year, we filed an application for manufacturing and marketing approval for cultured autologous corneal epithelium for the treatment of corneal epithelial stem cell deficiency. In July, we successfully had national insurance cover the autologous cultured epidermis JACE for the treatment of epidermolysis bullosa. We thus believe we made steady progress toward our goals under our new management structure.

Our resolutions for 2020

In 2020, we intend to advance our mission, “Making regenerative medicine common practice in treating patients”. To deliver regenerative medicine to more patients and to provide regenerative treatment to medical conditions suffered by more patients, we think it is important to further promote our products — the autologous cultured epidermis JACE and the autologous cultured cartilage JACC — to existing and new medical institution clients.
In 2020, Japan is going to host the Olympics, which will attract people from all over the world to Japan, drawing global attention. This will be a golden opportunity to promote to the world the regenerative medicine that we have steadily fostered in Japan. As the leading company in this field, we would like to deliver new products, services, and values to the world.

This year again, we will be enhancing our effort on the value and dissemination of regenerative medicine to provide many clients with a deeper understanding of our activities. We are committed to making 2020 a great year for you and to building a society in which it is more comfortable to live and one can stay healthy for a long time.

To our shareholders

In February last year, we thankfully celebrated our 20th anniversary. Please read "Topics on Regenerative Medicine 2", a newsletter we issued for our shareholders that explains regenerative medicine in Japan in plain language by reflecting on the past 20 years and focusing on the future development of regenerative medicine.
We would truly appreciate your continued understanding and support.

January 1, 2020
Japan Tissue Engineering Co., Ltd.

President & CEO Ken-ichiro Hata
Chairman & CEO
President & COO Masataka Akiyama
President & COO